2366 related articles for article (PubMed ID: 8331230)
21. Detection of malignancies with SPECT versus PET, with 2-[fluorine-18]fluoro-2-deoxy-D-glucose.
Martin WH; Delbeke D; Patton JA; Sandler MP
Radiology; 1996 Jan; 198(1):225-31. PubMed ID: 8539384
[TBL] [Abstract][Full Text] [Related]
22. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of whole-body cancer screening using 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography: a preliminary report.
Terauchi T; Murano T; Daisaki H; Kanou D; Shoda H; Kakinuma R; Hamashima C; Moriyama N; Kakizoe T
Ann Nucl Med; 2008 Jun; 22(5):379-85. PubMed ID: 18600415
[TBL] [Abstract][Full Text] [Related]
24. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison.
Agress H; Cooper BZ
Radiology; 2004 Feb; 230(2):417-22. PubMed ID: 14699176
[TBL] [Abstract][Full Text] [Related]
25. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose.
Steinert HC; Huch Böni RA; Buck A; Böni R; Berthold T; Marincek B; Burg G; von Schulthess GK
Radiology; 1995 Jun; 195(3):705-9. PubMed ID: 7753998
[TBL] [Abstract][Full Text] [Related]
26. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer.
Sazon DA; Santiago SM; Soo Hoo GW; Khonsary A; Brown C; Mandelkern M; Blahd W; Williams AJ
Am J Respir Crit Care Med; 1996 Jan; 153(1):417-21. PubMed ID: 8542152
[TBL] [Abstract][Full Text] [Related]
27. Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer.
Kim TS; Moon WK; Lee DS; Chung JK; Lee MC; Youn YK; Oh SK; Choe KJ; Noh DY
World J Surg; 2001 Jul; 25(7):829-34. PubMed ID: 11572019
[TBL] [Abstract][Full Text] [Related]
28. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary.
Han A; Xue J; Hu M; Zheng J; Wang X
Cancer Epidemiol; 2012 Oct; 36(5):470-5. PubMed ID: 22504050
[TBL] [Abstract][Full Text] [Related]
29. Uptake of 2-deoxy, 2-(18F) fluoro-D-glucose in bladder cancer: animal localization and initial patient positron emission tomography.
Harney JV; Wahl RL; Liebert M; Kuhl DE; Hutchins GD; Wedemeyer G; Grossman HB
J Urol; 1991 Feb; 145(2):279-83. PubMed ID: 1988718
[TBL] [Abstract][Full Text] [Related]
30. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET.
Kole AC; Nieweg OE; Pruim J; Paans AM; Plukker JT; Hoekstra HJ; Schraffordt Koops H; Vaalburg W
J Nucl Med; 1997 May; 38(5):692-6. PubMed ID: 9170429
[TBL] [Abstract][Full Text] [Related]
31. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes.
Younes-Mhenni S; Janier MF; Cinotti L; Antoine JC; Tronc F; Cottin V; Ternamian PJ; Trouillas P; Honnorat J
Brain; 2004 Oct; 127(Pt 10):2331-8. PubMed ID: 15361417
[TBL] [Abstract][Full Text] [Related]
32. Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability.
Scheidhauer K; Scharl A; Pietrzyk U; Wagner R; Göhring UJ; Schomäcker K; Schicha H
Eur J Nucl Med; 1996 Jun; 23(6):618-23. PubMed ID: 8662094
[TBL] [Abstract][Full Text] [Related]
33. Breast imaging with fluorine-18-FDG PET: quantitative image analysis.
Avril N; Bense S; Ziegler SI; Dose J; Weber W; Laubenbacher C; Römer W; Jänicke F; Schwaiger M
J Nucl Med; 1997 Aug; 38(8):1186-91. PubMed ID: 9255146
[TBL] [Abstract][Full Text] [Related]
34. FDG-PET evaluation of indeterminate pancreatic masses.
Ho CL; Dehdashti F; Griffeth LK; Buse PE; Balfe DM; Siegel BA
J Comput Assist Tomogr; 1996; 20(3):363-9. PubMed ID: 8626891
[TBL] [Abstract][Full Text] [Related]
35. PET FDG studies in oncology.
Hawkins RA; Hoh CK
Nucl Med Biol; 1994 Jul; 21(5):739-47. PubMed ID: 9241650
[TBL] [Abstract][Full Text] [Related]
36. [Cancer screening with whole-body FDG PET].
Yasuda S; Ide M; Takagi S; Shohtsu A
Kaku Igaku; 1996 Oct; 33(10):1065-71. PubMed ID: 8952258
[TBL] [Abstract][Full Text] [Related]
37. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
[TBL] [Abstract][Full Text] [Related]
38. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.
Dehdashti F; Mortimer JE; Siegel BA; Griffeth LK; Bonasera TJ; Fusselman MJ; Detert DD; Cutler PD; Katzenellenbogen JA; Welch MJ
J Nucl Med; 1995 Oct; 36(10):1766-74. PubMed ID: 7562040
[TBL] [Abstract][Full Text] [Related]
39. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose.
Wahl RL; Cody RL; Hutchins GD; Mudgett EE
Radiology; 1991 Jun; 179(3):765-70. PubMed ID: 2027989
[TBL] [Abstract][Full Text] [Related]
40. Focal fluorine-18 fluorodeoxyglucose-avid lesions without computed tomography correlate at whole-body positron emission tomography-computed tomography in oncology patients: how often are they malignant?
Kumar R; Hawkins RA; Yeh BM; Wang ZJ
Nucl Med Commun; 2011 Sep; 32(9):802-7. PubMed ID: 21685821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
